<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971578</url>
  </required_header>
  <id_info>
    <org_study_id>ASDCLAD001</org_study_id>
    <nct_id>NCT03971578</nct_id>
  </id_info>
  <brief_title>Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses</brief_title>
  <official_title>Screening Device for Autism Spectrum Disorders Using High Stimulation Rate ABR With Continuous Loop Averaging Deconvolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intelligent Hearing Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Intelligent Hearing Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop an Auditory Brainstem Response (ABR) based
      neurological screening method to detect increased risk for Autism Spectrum Disorders (ASD)
      and other neurological conditions in newborns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the proposed study, a screening method for neurological deficits, with an emphasis on its
      application to ASD, will be developed and its feasibility demonstrated. The proposed method
      will utilize high rate stimulation to acquire Auditory Brainstem Responses in order to
      determine peak latency and amplitude differences in children with ASD compared to non-ASD.
      Similarly to newborn hearing screening, the output of the screening method will provide an
      automated pass or refer outcome that can be used by a physician to determine if the child
      needs further evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ABR Peak Latency and Amplitude</measure>
    <time_frame>One Week</time_frame>
    <description>ABR Peak Latency and Amplitude</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Autism Spectrum Disorders Group</arm_group_label>
    <description>Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Control Group</arm_group_label>
    <description>Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention Provided</intervention_name>
    <description>No Intervention Provided</description>
    <arm_group_label>Autism Spectrum Disorders Group</arm_group_label>
    <arm_group_label>Normal Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with autism spectrum disorders and normally developing age- and gender-matched
        controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with autism spectrum disorder diagnosis

          -  Normally developing age- and gender-matched controls

        Exclusion Criteria:

          -  Permanent or temporary hearing loss at the time of testing.

          -  Craniofacial abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Months</minimum_age>
    <maximum_age>54 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine Delgado, PhD</last_name>
    <phone>305-284-2814</phone>
    <email>cdelgado@umiami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rafael Delgado, PhD</last_name>
    <phone>305-668-6102</phone>
    <email>redelgado@ihsys.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami Department of Psychology</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franchesca Izquierdo</last_name>
      <phone>305-284-2814</phone>
      <email>UMChildDevelopment@miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Delgado, PhD</last_name>
      <phone>305-284-2814</phone>
      <email>cdelgado@umiami.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miron O, Beam AL, Kohane IS. Auditory brainstem response in infants and children with autism spectrum disorder: A meta-analysis of wave V. Autism Res. 2018 Feb;11(2):355-363. doi: 10.1002/aur.1886. Epub 2017 Oct 31.</citation>
    <PMID>29087045</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism Spectrum Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Summary data will be disseminated</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

